Jump to main content.

Linuron Quickview (CASRN 330-55-2)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Linuron

File First On-Line: 03/31/1987; Last Significant Revision: 08/01/1989

Category (section)
Last Revised
Oral RfD Assessment Yes 03/31/1987
Inhalation RfC Assessment No
Carcinogenicity Assessment Yes 08/01/1989
  • 330-55-2
  • Afalon
  • Afalon inuron
  • Aphalon
  • Cephalon
  • 3-(3,4-Dichloor-fenyl)-1-methoxy-1-methylureum
  • 3-(3,4-Dichloro-fenil)-1-metossi-1-metil-urea
  • 3-(3,4-Dichlorophenyl)-1-methoxymethylurea
  • 3-(3,4-Dichlorophenyl)-1-methoxy-1-methylurea
  • 1-(3,4-Dichlorophenyl)3-methoxy-3-methyluree
  • 3-(3,4-Dichlor-phenyl)-1-methoxy-1-methyl-harnstoff
  • more...
Linuron Source Documents
Revision History
Date Section Description
04/01/1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
Abnormal blood pigment LEL : 6.25 x10-1 mg/kg-day 300 2 x10-3 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Reference Concentration for Chronic Inhalation Exposure (RfC)

Not Assessed under the IRIS Program.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • C (Possible human carcinogen)
  • Weight-of-Evidence Narrative:
    • Limited evidence indicated linuron produced increases in both testicular hyperplasia and adenomas in male rats in three separate studies. Hepatocellular adenomas were observed in female mice in a single study at the highest dose group tested; the tumors were benign and showed no progression toward malignancy.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Information reviewed but value not estimated. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Not Assessed under the IRIS Program.

Top of page

Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research

Local Navigation

Jump to main content.